Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Oct 2013 08:48

Adept Telecom: Northland Capital revises target price from 145p to 165p and reiterates a buy recommendation.Aggreko: JP Morgan reduces target price from 1620p to 1505p, while its neutral recommendation remains unchanged. UBS cuts target price from 1610p to 1555p keeping its neutral rating.APR Energy: Investec raises target price from 900p to 1150p and stays with its hold recommendation.ARM Holdings: RBC Capital moves target price from 1050p to 1080p and retains an outperform rating.Barratt Developments: Liberum Capital ups target price from 374p to 387p and maintains a buy recommendation.Bellway: Liberum Capital takes target price from 1700p to 1760p and retains its buy recommendation.Berkeley Group: Liberum Capital raises target price from 2400p to 2634p, while reiterating a hold recommendation.Blur Group: Liberum Capital raises target price from 400p to 700p and stays with its buy recommendation.Bovis Homes Group: Liberum Capital increases target price from 791p to 911p upgrading to buy.Braemer Shipping Services: Westhouse Securities takes target price from 515p to 590p and reiterates an add rating.BT Group: Bank of America ups target price from 350p to 400p retaining a buy recommendation.Coca-Cola HBC: Nomura reduces target price from 1600p to 1500p and downgrades from neutral to reduce.EMIS Group: N+1 Singer takes target price to 748p upgrading from hold to buy.Europa Oil & Gas: Northland Capital shifts target price from 17.60p to 19.70p and stays with its buy recommendation.Genel Energy: RBC Capital revises target price from 1100p to 1300p and maintains an outperform rating.Getech: WH Ireland shifts target price from 86p to 92p staying with its buy recommendation.GlaxoSmithKline: Barclays lowers target price from 1555p to 1545p and retains an equal-weight rating.Halfords Group: Investec ups target price from 400p to 460p and maintains its buy recommendation.HSBC Holdings: Goldman Sachs cuts target price from 950p to 900p, while reiterating its strong buy recommendation.ITV: Berenberg raises target price from 91p to 155p, but downgrades from hold to sell.Kirkland Lake Gold: Investec cuts target price from 377p to 353p, while its buy recommendation is kept.Lloyds Banking Group: Goldman Sachs shifts target price from 75p to 76p and maintains a neutral rating. Numis downgrades to hold with a target price of 85p.Microgen: Investec lowers target price from 147p to 143p and keeps a hold recommendation. Westhouse Securities cuts target price from 155p to 145p, while upgrading to add.Next Fifteen Communications: Canaccord Genuity reduces target price from 120p to 94p downgrading from buy to hold.Persimmon: Liberum Capital takes target price from 1245p to 1261p, while its hold recommendation remains unaltered.Playtech: Investec places its target price (prev.: 630p) under review, while staying with its hold recommendation. Canaccord Genuity raises target price from 780p to 825p retaining its buy recommendation. Daniel Stewart increases target price from 790p to 840p and keeps its buy recommendation.Redrow: Liberum Capital ups target price from 241p to 304p and upgrades to buy.Regus: Investec downgrades from buy to add with a target price of 205p.Salamander Energy: RBC Capital cuts target price from 250p to 170p downgrading to neutral.Shire: Barclays increases target price from 2515p to 2800p, while its overweight rating is kept.Stagecoach: Investec places its target price (prev.: 325p) under review, while leaving its add rating unchanged.Standard Chartered: Goldman Sachs reduces target price from 1900p to 1700p leaving its neutral rating unaltered.Taylor Wimpey: Liberum Capital moves target price from 113p to 127p and keeps a buy recommendation.
More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.